Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach

Cutaneous malignant melanoma (CMM) is one of the most common skin cancers worldwide. Limited information is available in the current scientific literature on the concordance of genetic alterations between primary and metastatic CMM. In the present study, we performed next-generation sequencing (NGS) analysis of the main genes participating in melanoma pathogenesis and progression, among paired primary and metastatic lesions of CMM patients, with the aim to evaluate levels of discrepancies in mutational patterns. Paraffin-embedded tumor tissues of the paired lesions were retrieved from the archives of the institutions participating in the study. NGS was performed using a specific multiple-gene panel constructed by the Italian Melanoma Intergroup (IMI) to explore the mutational status of selected regions (343 amplicons; amplicon range: 125–175 bp; coverage 100%) within the main 25 genes involved in CMM pathogenesis; sequencing was performed with the Ion Torrent PGM System. A discovery cohort encompassing 30 cases, and a validation cohort including eleven Sardinian patients with tissue availability from both the primary and metachronous metastatic lesions were identified; the global number of analyzed tissue specimens was 90. A total of 829 genetic non-synonymous variants were detected: 101 (12.2%) were pathogenic/likely pathogenic, 131 (15.8%) were benign/likely benign, and the remaining 597 (72%) were uncertain/unknown significance variants. Considering the global cohort, the consistency in pathogenic/pathogenic like mutations was 76%. Consistency for BRAF and NRAS mutations was 95.2% and 85.7% respectively, without statistically significant differences between the discovery and validation cohort. Our study showed a high level of concordance in mutational patterns between primary and metastatic CMM, especially when pathogenic mutations in driver genes were considered.

• Publication year

  2019

• Venue

  Journal of Translational Medicine

• Publication date

  2019-08-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/s12967-019-2039-4PMID 31455347PMCID 6712827
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives

  2020cited by this paper
• Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

  2019cited by this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

  2019cited by this paper
• The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes

  2019cited by this paper
• BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas

  2019cited by this paper
• Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.

  2018cited by this paper
• Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches

  2018cited by this paper
• Chemotherapy and Biochemotherapy for Melanoma

  2018cited by this paper
• Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas

  2018cited by this paper
• Melanoma

  2018cited by this paper
• Genetic alterations in main candidate genes during melanoma progression

  2018cited by this paper
• The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases

  2017cited by this paper
• Epidemiology and genetic susceptibility of malignant melanoma in North Sardinia, Italy

  2017cited by this paper
• Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel

  2017cited by this paper
• Validation of an NGS mutation detection panel for melanoma

  2017cited by this paper
• Intratumor and Intertumor Heterogeneity in Melanoma

  2017cited by this paper
• BRAF Mutation Status Concordance Between Primary Cutaneous Melanomas and Corresponding Metastases: A Review of the Latest Evidence.

  2017cited by this paper
• Somatic mutation analysis in melanoma using targeted next generation sequencing.

  2017cited by this paper
• Whole-genome landscapes of major melanoma subtypes

  2017cited by this paper
• BRAF Mutation Status Concordance Between Primary Cutaneous Melanomas and Corresponding Metastases: A Review of the Latest Evidence

  2017cited by this paper
• Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel

  2017cited by this paper
• Concordancia mutacional de BRAF entre melanoma primario cutáneo y sus correspondientes metástasis. Revisión de la evidencia actual

  2017cited by this paper
• Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma.

  2016cited by this paper
• Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets

  2015cited by this paper
• Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy

  2015cited by this paper
• Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors.

  2015cited by this paper
• Genomic Classification of Cutaneous Melanoma.

  2015cited by this paper
• Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma

  2014cited by this paper
• Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site

  2014cited by this paper
• Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.

  2014cited by this paper
• Melanoma genome sequencing reveals frequent PREX2 mutations

  2012cited by this paper
• A landscape of driver mutations in melanoma.

  2012cited by this paper
• Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia

  2012cited by this paper
• Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

  2012cited by this paper
• BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

  2012cited by this paper
• Molecular Diagnostics

  2011cited by this paper
• Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy

  2009cited by this paper
• Publisher's Note

  2003cited by this paper
• NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

  2003cited by this paper

• Clinical, Histopathological, Dermoscopic Features, and BRAF, NRAS, and Cell Cycle Genes’ Mutation Status in Cutaneous Melanoma

  2025cites this paper
• Association of the BRAFV600E mutation with morphology and heterogeneity in melanoma.

  2025cites this paper
• Integrating generative AI with ABCDE rule analysis for enhanced skin cancer diagnosis, dermatologist training and patient education

  2024cites this paper
• Cancer, metastasis, and the epigenome

  2024cites this paper
• Synchronous collision metastasis of melanoma and squamous cell carcinoma in a parotid lymph node: a very rare occurrence and literature review.

  2024cites this paper
• Identification of genetic fingerprint of type I interferon therapy in visceral metastases of melanoma

  2024cites this paper
• KRAS and BRAF genetic alterations in lung cancer: A case - control study.

  2024cites this paper
• Mutational Profiles of Cutaneous Squamous Cell Carcinomas with Different Patterns of Clinical Aggression from Head and Neck Regions

  2024cites this paper
• Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel

  2024cites this paper
• Differences in the Clinical and Molecular Profiles of Subungual Melanoma and Acral Melanoma in Asian Patients

  2023cites this paper
• The Genomic Landscape of Melanoma and Its Therapeutic Implications

  2023cites this paper
• Prognostic and predictive biomarkers in melanoma.

  2023cites this paper
• Genetic Concordance in Primary Cutaneous Melanoma and Matched Metastasis: A Systematic Review and Meta-Analysis

  2023cites this paper
• Detection and Localization of Solid Tumors Utilizing the Cancer-Type-Specific Mutational Signatures

  2022cites this paper
• Oncogenic alterations reveal key strategies for precision oncology in melanoma treatment

  2022cites this paper
• Tissue Displacement Versus Two Primary Colorectal Carcinomas? A Case Report on the Utility of Comparative Sequencing.

  2022cites this paper
• Genomic and Transcriptional Profiling of Chinese Melanoma Patients Enhanced Potentially Druggable Targets: A Multicenter Study

  2022cites this paper
• Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer

  2021cites this paper
• Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

  2021cites this paper
• Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era

  2021cites this paper
• Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies

  2021cites this paper
• BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center

  2021cites this paper
• The BRAF P.V600E Mutation Status of Melanoma Lung Metastases Cannot Be Discriminated on Computed Tomography by LIDC Criteria nor Radiomics Using Machine Learning

  2021cites this paper
• Primary tumor characteristics and next‐generation sequencing mutations as biomarkers for melanoma immunotherapy response

  2020cites this paper
• The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas

  2020cites this paper
• Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI)

  2020cites this paper
• Collaborative, Multidisciplinary Evaluation of Cancer Variants Through Virtual Molecular Tumor Boards Informs Local Clinical Practices

  2020cites this paper
• Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives

  2020cites this paper
• The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes

  2019cites this paper
• BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas

  2019cites this paper
• The Hidden Story on Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma – Association with Clinical Outcome and Tumor Phenotypes

  2019cites this paper